Simulations Plus, Inc. (SLP) is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the pharmaceutical industry for research, product enhancement, and to facilitate development of new therapeutic drugs. The company operates globally, providing advanced modeling and simulation tools for novel drug discovery and the promotion of enhanced health benefits worldwide.
The company was founded in 1996 and is based in Lancaster, California. It is publicly traded on the NASDAQ stock exchange under the ticker symbol ‘SLP’. Simulations Plus has earned acclaim for its advanced and comprehensive software that integrates the best-in-class features and technologies. The company offers a diverse portfolio that spans across several innovative software products designed to predict properties of molecules, as well as their biological and pharmacological behaviors.
One of the key products of Simulations Plus is the GastroPlus™ program, which is a mechanistic, physiologically based pharmacokinetic/pharmacodynamics modeling platform that simulates the absorption, distribution, metabolism, and excretion of drugs in humans and animals. This product assists in the prediction of a drug's potential success or failure early in the development process, cutting down risk and costs tied to drug discovery and development.
In addition to GastroPlus, Simulations Plus has developed other tools like DDDPlus™, MembranePlus™, and more – each designed to cater to the unique needs of pharmaceutical research. The company's most recent addition to its product portfolio, ADMET Predictor®, tackles absorption, distribution, metabolism, excretion, and toxicity of potential drug candidates.
Simulations Plus has a strong customer base that includes top pharmaceutical and bio-tech companies, research institutes, and regulatory agencies worldwide. They serve a key role in aiding these organizations make crucial decisions on drug development.
One of the hallmarks of Simulations Plus is their commitment to continuous development and improvement. Recognizing the speed of technological evolution, the company continually expands and refines its software to stay at the forefront of the industry. They have also been continuously investing in enhancing their in-house capabilities towards developing more efficient simulation software to help companies make effective and efficient clinical decisions.
The diligent efforts of Simulations Plus, Inc. have resulted in transforming the dynamics of predictive modeling for the pharmaceutical industry. It's a company that combines technological innovation with deep expertise in pharmaceuticals to revolutionize drug discovery and development.